Your browser is no longer supported. Please, upgrade your browser.
Theravance Biopharma, Inc.
Index- P/E- EPS (ttm)-4.11 Insider Own5.30% Shs Outstand65.67M Perf Week-20.19%
Market Cap487.72M Forward P/E18.64 EPS next Y0.37 Insider Trans0.00% Shs Float61.17M Perf Month-49.00%
Income-264.20M PEG- EPS next Q-0.55 Inst Own84.80% Short Float3.43% Perf Quarter-60.82%
Sales64.20M P/S7.60 EPS this Y-4.90% Inst Trans14.25% Short Ratio1.63 Perf Half Y-66.31%
Book/sh-4.57 P/B- EPS next Y46.50% ROA-59.20% Target Price- Perf Year-61.39%
Cash/sh3.74 P/C1.84 EPS next 5Y54.10% ROE85.30% 52W Range6.10 - 22.74 Perf YTD-61.28%
Dividend- P/FCF- EPS past 5Y3.50% ROI-96.60% 52W High-69.70% Beta0.89
Dividend %- Quick Ratio5.00 Sales past 5Y11.30% Gross Margin- 52W Low12.95% ATR0.74
Employees359 Current Ratio5.00 Sales Q/Q-14.00% Oper. Margin- RSI (14)26.30 Volatility10.52% 7.22%
OptionableYes Debt/Eq- EPS Q/Q20.20% Profit Margin- Rel Volume0.42 Prev Close6.88
ShortableYes LT Debt/Eq- EarningsAug 03 AMC Payout- Avg Volume1.29M Price6.89
Recom2.60 SMA20-18.63% SMA50-39.90% SMA200-59.09% Volume335,541 Change0.15%
Sep-15-21Downgrade JP Morgan Overweight → Underweight $7
Aug-25-21Downgrade Morgan Stanley Overweight → Underweight $27 → $14
Aug-24-21Downgrade Cowen Outperform → Market Perform $42 → $14
Oct-14-20Upgrade Morgan Stanley Equal-Weight → Overweight $32
Jul-07-20Initiated JP Morgan Overweight $29
Jun-15-20Initiated Morgan Stanley Equal-Weight $30
May-13-20Initiated Cowen Outperform $42
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-06-19Upgrade Robert W. Baird Underperform → Neutral $22 → $18
Oct-29-19Initiated H.C. Wainwright Buy $25
Mar-29-18Resumed Piper Jaffray Overweight $45
Aug-17-17Initiated Evercore ISI Outperform $45
Jun-16-17Initiated Cantor Fitzgerald Overweight $55
May-11-17Reiterated Needham Buy $40 → $45
Dec-21-16Initiated Needham Buy $40
Nov-03-16Initiated Piper Jaffray Overweight
Oct-12-16Downgrade Robert W. Baird Neutral → Underperform $19 → $24
Aug-03-16Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16Reiterated Leerink Partners Outperform $26 → $29
Jun-20-16Initiated Guggenheim Buy $30
Sep-21-21 10:00AM  
Sep-17-21 07:40AM  
Sep-16-21 10:55AM  
Sep-15-21 05:13PM  
Sep-02-21 11:31AM  
Aug-26-21 12:56PM  
Aug-24-21 04:05PM  
Aug-23-21 04:51PM  
Aug-09-21 01:39AM  
Aug-04-21 10:01AM  
Aug-03-21 05:25PM  
Aug-02-21 10:26AM  
Jul-27-21 03:03PM  
Jul-20-21 06:00AM  
Jul-02-21 10:55AM  
Jun-24-21 10:56PM  
Jun-22-21 09:51AM  
Jun-21-21 07:37AM  
Jun-03-21 11:31AM  
May-09-21 04:50AM  
May-06-21 06:00AM  
May-05-21 10:45AM  
May-04-21 05:20PM  
Apr-21-21 03:22AM  
Apr-20-21 06:00AM  
Mar-25-21 11:30AM  
Mar-04-21 04:13AM  
Mar-02-21 06:00AM  
Feb-24-21 06:32AM  
Feb-23-21 04:45PM  
Feb-22-21 10:16AM  
Feb-10-21 06:00AM  
Feb-09-21 06:00AM  
Jan-14-21 12:00PM  
Jan-05-21 06:00AM  
Dec-19-20 01:06PM  
Dec-05-20 11:32AM  
Nov-17-20 06:00AM  
Nov-09-20 12:17PM  
Nov-07-20 01:31AM  
Nov-05-20 07:05PM  
Oct-29-20 12:34PM  
Oct-27-20 01:19PM  
Oct-22-20 06:00AM  
Oct-19-20 10:39AM  
Sep-05-20 11:31AM  
Sep-01-20 06:00AM  
Aug-07-20 01:27PM  
Aug-06-20 06:35PM  
Jul-30-20 12:34PM  
Jul-27-20 06:00AM  
Jul-22-20 12:32PM  
Jul-02-20 06:00AM  
Jun-29-20 03:50PM  
Jun-26-20 12:04PM  
Jun-25-20 08:26AM  
Jun-17-20 09:38PM  
Jun-15-20 09:57AM  
Jun-05-20 11:31AM  
Jun-02-20 09:02PM  
May-08-20 02:31PM  
May-07-20 01:57PM  
May-06-20 07:35PM  
Apr-29-20 12:33PM  
Apr-28-20 12:33PM  
Apr-23-20 06:00AM  
Apr-20-20 06:00AM  
Apr-14-20 04:41PM  
Apr-09-20 07:00AM  
Mar-25-20 11:30AM  
Mar-23-20 06:32PM  
Mar-20-20 08:02PM  
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WORBOYS PHILIP DSVP, Research & Transl ScienceMar 09Sale20.008,829176,580343,679Mar 11 07:00 PM
GRAHAM RICHARD ASVP, DevelopmentDec 14Sale19.477,500146,058123,749Dec 16 06:09 PM
WORBOYS PHILIP DSVP, Research & Transl ScienceDec 03Sale18.004,24676,428319,395Dec 07 06:42 PM